Gilead Sciences, Inc. and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a Phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and ACC inhibitor firsocostat, alone and in combination in people with compensated cirrhosis due to NASH.   The study in ap...